BOLLÉ-SAFETY
19.4.2021 10:32:04 CEST | Business Wire | Press release
Global eye protection specialist Bollé Safety now provides Trivex. A high-performance, high-technology prescription lens providing maximum security and great optical properties to ensure the best safety in a work environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419005013/en/
The best of CR39 and polycarbonate in addition to unique features.
Bollé Safety’s latest lens material combines CR39’s lightness and polycarbonate’s durability. With a featherweight density (1,11g/cm3), Trivex is the lightest corrective lens material on the market. It also offers very good optical properties, superior to polycarbonate. The Trivex technology corrects some drawbacks traditionally attached to CR39 and polycarbonate. The lens is 20% thinner than CR39 and is shatterproof. Unlike polycarbonate, it is chemical and solvent resistant, making it safe to operate in a variety of work environments. Special new features include a 100% efficient UV filter that absorbs the totality of UVA and UVB for even better eye protection. And to ensure long-lasting aesthetics, the lens doesn’t turn yellow over time.
Why go to Bollé Safety to switch to Trivex?
Trivex properties are so high-performing that its technology was initially used for military purposes. With half of the global population over 20 years old suffering from vision problems, companies have a crucial interest in providing their workers with safety prescription eyewear that ensures optimal protection. Poor vision can lead to massive productivity losses and classic safety eyewear is not a one-size-fits-all product. Did you know that 90% of eye injuries could be prevented with proper protection and care? Wearing adapted and fitted eyewear can be a game-changer for professionals. Bollé Safety offers several ranges of products for plano and prescription lenses, so everyone can have perfect vision and safe working conditions. Bollé Safety’s latest frames, “KLASSEE” and “KURT”, make the most out of the Trivex technology. Thanks to Bollé’s unique global expertise, the KLASSEE model combines bio-sourced materials with side protections on the top and on the bottom of the frames. KURT is a great option with adjustable reinforced arms and an athletic frame for even more protection. The translucent front has been smoked to optimize side vision without being blinded. Lightweight and flexible, Bollé Safety glasses ensure a comfortable and secure experience and diminish risks in the work environment.
For more information, visit https://bit.ly/3e0A43j
About Bollé Safety.
Bollé Safety, the global brand for eye protection. Over our 130 years of existence, we have created more than 500 models of safety glasses. With a wide range of innovative, comfortable, and protective safety and prescription eyewear, we are trusted with the protection of over 20 million workers’ vision in 100 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005013/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom